Episode description
Episode description
Stocks ending the day near their highs of the session with the Nasdaq notching its first record close since November 2021. But in a month that saw broad strength in the market, a couple names really stood out. Do you stick with the big winners into March? Or will some of this month’s laggards gain some spring in their step? Plus, unapproved copycat versions of obesity drugs could throw a wrench in the red-hot market. The impact on users, and the stocks tipping the scales in the weight loss wars.